Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4583 Improved assessment of gene rearrangements by targeting non-coding DNA regions in patients diagnosed with pancreatic neuroendocrine neoplasms

Introduction: Whole-genome sequencing projects documented the heterogeneity of pancreatic neuroendocrine neoplasms (PanNEN), while showing that few core pathways are consistently affected in their tumorigenesis. Comprehensive genomic profiling (CGP) of real-world cases is expected to recapitulate such heterogeneity for patient stratification and to inform precision therapy. While coding DNA is the focus of current CGP panels, the potential of targeting non-coding DNA (ncDNA) to improve structural variants detection has not been widely explored in this context.

Conference:

Presenting Author: Agnoletto C

Authors: Agnoletto C, Trevisani E, Borghesani M, Landoni L, Luchini C,

Keywords: neuroendocrine, non-coding DNAs, structural variants, clinical relevance, CGP panel,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4519 ANXA1-labelled cancer-associated fibroblasts induces tumour invasion and immunosuppressive microenvironment

Introduction: The growth pattern of a tumour is a marker for distinguishing inert from invasive tumours. In general, tumours such as the encapsulated follicular variant of papillary thyroid carcinoma show expansive growth. In contrast, invasive tumours, such as colorectal cancer and squamous cell carcinoma of the tongue, show invasive growth with infiltration into surrounding structures and have a poorer prognosis. Pancreatic neuroendocrine neoplasm (PNEN) is the heterogeneous tumour originating from peptidergic neurons and neuroendocrine cells. PNEN with a high proportion of tumour mesenchyme, especially those presenting an infiltrating stroma, have a poor prognosis. In the infiltrating mesenchyme, cancer-associated fibroblasts (CAF) play an important role. However, little research has been done on the mechanisms of how infiltrating CAF affects tumour malignancy and immune microenvironment.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Xu J, Chen J, Xu X, Ji S,

Keywords: pancreatic neuroendocrine neoplasm, tumour-associated fibroblasts, immunosuppressive microenvironment,